Prostate Cancer Therapeutics : Market Research Report

Prostate Cancer Therapeutics

Published by: Global Industry Analysts

Published: Apr. 1, 2009 - 739 Pages

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS: Study Reliability and Reporting Limitations; Disclaimers; Product Definitions and Scope of Study; Radiation Therapy
II. EXECUTIVE SUMMARY: 1.Industry Overview; Key Prostate Cancer Drugs & Companies; Select Prostate Cancer Hormonal Therapy Drugs withYear of FDA Approval; Innovations in Drug Delivery: A Key Factor in ProductDifferentiation; Small Cap Companies: A Target of Private CapitalFinancing; Awareness Drives European Prostate Cancer TherapeuticsMarket; Table 3: New Cancer Cases Diagnosed in the USin 2007: Percentage Share by LeadingCancer Sites (includes correspondingGraph/Chart); Table 5: Male Population by Age Group in the USfor the year 2007 (includes correspondingGraph/Chart); Select FDA Approved Drugs for Palliative Treatmentof Advanced Prostate Cancer; Table 7: Five-Year Cancer Survival Rate Among USMales by Type - Prostate and Testis (1996-2002)(includes corresponding Graph/Chart); Molecular Imaging of Cancer: Critical in ImprovingPatient Outcomes; Multiple Drug Resistance; Notable Prostate Cancer Drug Failures in Phase IIIDevelopment; 2.Clinical Trials; Select Prostate Cancer Drugs Under Phase II/III Trialsby Leading Companies; Drugs in Pre-Clinical Stage; 3.Product Overview; Table 11: Cancer Death Rates in the US (2007):Percentage Breakdown by Cancer Type - Lung &Bronchus, Prostate, Colon & Rectum, Pancreas,Leukemia, and Others (includes correspondingGraph/Chart); Pituitary Gland; Prostate Cancer - A Primer; Table 14: New Incidences of Prostate Cancer (in ‘000) Worldwide for the years 2007 and 2008 (includes corresponding Graph/Chart); Table 15: Mortality Due to Prostate Cancer (in ‘000) Worldwide for the Years 2007 and 2008 (includes corresponding Graph/Chart); Table 16: Male Population (in Million) for the Year2007 for Select Regions (includes corresponding Graph/Chart); Screening/Detection of Prostate Cancer; Improved PSA Testing; Microbubble Ultrasound; Gleason Score; Genetic & Non-Genetic Factors; Table 17: Prostate Cancer Incidence/Mortality Rateby Race & Ethnicity in US, 1999-2003 (includescorresponding Graph/Chart); Prevention of Cancer; 4.Treatment Options for Prostate Cancer; LHRH Analogs; Anti-Androgens; Orchiectomy; Strategies to Enhance Hormonal Treatment; Treatment Procedure; Benefits of Brachytherapy; High Dose Rate (HDR) Brachytherapy; Whole Pelvic Radiation Therapy (WPRT); Risks Associated with Chemotherapy; Prostatectomy and Lymph Node Dissection; Cryosurgery; Benefits of IMRT; High Dose Radiation (HDR) Monotherapy; Recurrent Prostate Cancer; Recurrent Prostate Cancer Subsequent toRadiation Therapy; TCaxotere® (Docetaxel); Doxazosin, a Cytotoxic Drug for Prostate Cancer; Phase I Clinical Trials; Selective Endothelia A Receptor Antagonist -(SERA™); Other Select Targeted Therapies; 5.Drug Approvals and Clinical Studies; Cougar Conducts Phase I/II Clinical Trials on CB7630in Patients with Prostate Cancer; Bioponic Phytoceuticals Unveils Pre-Clinical Data onCurecumin™ for Prostate Cancer; Cell Therapeutics Reveals Phase 2 Clinical Trial Resultsof XYOTAX™ in Androgen Independent ProstateCancer Patients; Cleveland BioLabs to Initiate Phase II Clinical Trial forCuraxin in HRPC; Marshall Edwards Conducts Study on Phenoxodiolin Prostate Cancer; University of California’s Analyses Support Dendreon’sActive Cellular Immunotherapy; Panacea Pharmaceuticals Identifies Blood Protein forEarly Prostate Cancer Detection; Active Biotech Reveals Results of TASQ Phase I Studyfor Prostate Cancer; Balanced Intake of Omega-6 and Omega-3 Fatty AcidsFound to Reduce Prostate Cancer Growth; Protox Gains Clearance from FDA to Conduct Phase ITrial of PRX302; Biomira Announces Results of Stimuvax Phase2 Clinical Study; PNNL and IsoRay Develops Cesium-131 Seed forTreatment of Prostate Cancer; 6.Product Innovations/Introductions; Barr Unveils Generic Version of Proscar® Tablets; 7.Recent Industry Activity; Celera Enters into Licensing Agreement with Merck; GPC Biotech and Celgene Terminate Agreement forSatraplatin; Morphotek® Enters into Licensing Agreementwith NCI; Sirnaomics Extends Partnership with GRL to DevelopMulti-Targeted RNAi Therapeutic Products; Cougar Biotech Enters into an Agreement with US FDA; MacroArray Partners with Abbott on PCADM-1 Testfor Prostate Cancer; Sagemark Embarks on Radiation Therapy Venture; Core Oncology Completes Acquisition of Coloplast’sBrachytherapy Business; GSK Acquires Praecis Pharmaceuticals; MedMira Inks Agreement to Take Over Rights ofa New Marker Technology; Signet Enters into Agreement with AsymmetRx toDistribute ‘Prostate-63’ Tests; Progenics Pharmaceuticals Broadens Association withSeattle Genetics; Progenics Pharmaceuticals Acquires PSMA DevelopmentCompany; Indevus Enters into Agreement to Takeover Valera; Altana Divests Entire Stake in GPC Biotech; Valera and Spepharm Partner to Market Vantas, andSupprelin-LA; MediGene Introduces Prostate Cancer Drug in ItalianMarket; Protox Acquires PRX321 Cancer Program fromUS Public Health Service and Neurocrine; Paladin Signs an Agreement with Watson for Supply andSale of Trelstar®; Caprion and AstraZ eneca Enter into Collaboration; National Cancer Institute Enters into Agreementwith Illumina; 8.Focus on Select Global Players; Amgen Inc. (USA); Medimmune, LLC (USA); Dendreon Corporation (USA); F. Hoffmann-La Roche Ltd. (Switzerland); GlaxoSmithKline Plc (UK); Novartis AG (Switzerland); Paladin Labs Inc. (Canada); Sanofi-Aventis SA (France); 9.Global Market Perspective; Table 19: World 10-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Europe, and Rest ofWorld Markets for Years 2006, 2009 & 2015(includes corresponding Graph/Chart)
III. MARKET: 1.The United States; Table 21: Male Population by Age Group in the USfor the Year 2007 (includes corresponding Graph/Chart); Market Challenges; Key Statistics; Table 26: New Cancer Cases Diagnosed in the US in 2007: Percentage Share by Leading Cancer Sites (includes corresponding Graph/Chart); Table 28: Mortality Due to Prostate Cancer in the US: Breakdown by Leading States for the Years 2007 and 2008 (includes corresponding Graph/Chart); Table 30: Comparison of Mortality Among African Americans and Whites by Cancer Type in the US,2000-2004 (includes corresponding Graph/Chart); Table 32: Five-Year Cancer Survival Rate Among US Males by Type - Prostate and Testis (1996-2002) (includes corresponding Graph/Chart); Table 34: Prostate Cancer Incidence/Mortality Rate by Race & Ethnicity in US, 1999-2003 (includes corresponding Graph/Chart); Product Launches; Select Players; B. Market Analytics; 2.Europe; Table 37: Mortality Due to Prostate Cancer inEurope: Breakdown by Region/ Country forthe Years 2007 and 2008 (In ‘000)(includes corresponding Graph/Chart); Product Launches; B. Market Analytics; Table 39: European 10-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, United Kingdom, Spain, and Rest ofEurope Markets for Years 2006, 2009 & 2015(includes corresponding Graph/Chart); 2a.France; Strategic Corporate Developments; Select Players; B. Market Analytics; 2b.Germany; GPC Biotech AG - A Major Player; 2c.Italy; B. Market Analytics; 2d.The United Kingdom; Product Launch; Select Players; B. Market Analytics; 2e.Spain; B. Market Analytics; 2f.Rest of Europe; Select Players; B. Market Analytics; 3.Rest of World; Table 48: Prostate Cancer Market in Canada (2008): New Cases and Deaths Due to Prostate Cancerby Age Group; Select Canadian Players; A Glance into Other Select Markets; Cancer Market in Asia; Malaysia; Cancer Market in Latin America; Table 52: Mortality Due to Prostate Cancer inLatin America: Breakdown by Region/ Countryfor the Years 2007 and 2008 (includescorresponding Graph/Chart); Strategic Corporate Developments; Select Players; B. Market Analytics
IV. COMPETITIVE LANDSCAPE: Total Companies Profiled: 138 (including Divisions/Subsidiaries - 153); Region/Country Players; The United States; Canada; Japan; Europe; Asia-Pacific (Excluding Japan)

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/14/2012 - 32

Prostate Cancer Therapeutics

Table of Contents

Abstract